Bromocriptine 1.25 mg Australia

Description

Introduction

Bromocriptine 1.25 mg Australia is presented as an oral tablet containing bromocriptine at a stated strength of 1.25 mg. Bromocriptine acts on dopamine receptors. Its appropriate use depends on the condition being treated and the formulation supplied.

This product is categorised for type 2 diabetes. Whether this particular tablet is intended or approved for that use in Australia cannot be confirmed from its product details. Ask a healthcare professional for product-specific guidance.

What Is It?

Bromocriptine is an ergot-derived dopamine agonist. Dopamine is a chemical messenger involved in processes that include prolactin release and movement control. Different bromocriptine products have different strengths, formulations and authorised uses.

The inactive ingredients and release characteristics of this 1.25 mg tablet are unspecified. People who need to check an ingredient because of an allergy or intolerance should consult a pharmacist and the packaging supplied with the medicine.

How Does It Work?

Bromocriptine stimulates dopamine receptors, particularly D2 receptors. In the pituitary gland, this reduces the release of prolactin. It can also lower growth hormone levels in some people with acromegaly. Its dopamine-related effects may help manage symptoms of Parkinson’s disease.

A distinct bromocriptine formulation is approved in the United States to improve blood glucose control in adults with type 2 diabetes when used alongside diet and exercise. Its glucose-lowering mechanism is not fully understood. That approval does not establish the use, formulation or approval status of this 1.25 mg tablet.

Common Uses

Bromocriptine has recognised uses for certain conditions involving elevated prolactin, including some prolactin-secreting pituitary tumours. It is also used in selected circumstances for acromegaly and Parkinson’s disease. The applicable indications depend on the specific medicine and clinical situation.

Type 2 diabetes is stated as an indication for this product, but that claim needs confirmation for the exact tablet supplied. Other bromocriptine products should not be assumed to have the same indications. A prescriber or pharmacist can clarify the intended use.

Available Strengths

This family is available in 1.25 mg, 2.5 mg.

Key Features

• Presented as an oral tablet containing bromocriptine at a stated strength of 1.25 mg.
• Bromocriptine acts on dopamine receptors and reduces prolactin release.
• The tablet’s inactive ingredients and release characteristics need confirmation from its packaging.
• Indications and directions must be checked for the specific product supplied.

Benefits

• Bromocriptine can reduce elevated prolactin when prescribed for an appropriate condition.
• It can lower growth hormone levels in selected people with acromegaly.
• It can help manage certain symptoms of Parkinson’s disease when used for an appropriate patient.
• These established effects do not confirm that this tablet is suitable for every condition associated with bromocriptine.

Possible Side Effects

• Nausea, vomiting, constipation, headache and dizziness may occur.
• Low blood pressure on standing can cause light-headedness or fainting.
• Drowsiness and sudden sleep onset have been reported. Alertness should be assessed before driving or using machinery.
• Confusion, hallucinations and changes in impulse control can occur and should be discussed with a healthcare professional.
• Severe headache, chest pain, breathing difficulty, new visual problems or signs of an allergic reaction require prompt medical assessment.
• Serious fibrotic changes affecting heart valves, the lungs or other tissues have been associated with bromocriptine treatment.

Precautions

• A healthcare professional should assess any history of heart valve disease, fibrotic disorders or uncontrolled high blood pressure.
• Pregnancy, plans for pregnancy and breastfeeding need discussion because bromocriptine affects prolactin and milk production.
• Mental health conditions, stomach ulcers, liver problems, fainting and pronounced sleepiness are relevant to treatment decisions.
• Allergy to bromocriptine, other ergot medicines or an ingredient of the supplied tablet needs assessment before use.

Additional Precautions

• Monitoring may include blood pressure checks and assessment for heart, lung or nervous system symptoms.
• People also using diabetes medicines should ask how blood glucose will be monitored if this tablet has been prescribed for that condition.
• New breathlessness, persistent cough, swelling, severe headache or visual changes should be assessed promptly.
• A 1.25 mg tablet should not be assumed interchangeable with another bromocriptine formulation solely because the active ingredient is shared.

Storage Instructions

• Follow the storage directions on the packaging supplied with this product; exact requirements for this tablet are unspecified.
• Keep the tablets in their supplied packaging and out of children’s reach.
• Follow any label directions about protection from heat, moisture or light.
• Do not use tablets after their expiry date or if the packaging appears damaged. Ask a pharmacist about disposal.

How to Take

• Follow the prescription and the directions on the supplied medicine label.
• Ask a pharmacist to confirm the formulation and intended use, particularly if the tablet has been selected for type 2 diabetes.
• Directions for one bromocriptine formulation should not be applied to another product.
• Seek product-specific advice about a missed dose or any proposed change to treatment.

Drug Interactions

• Certain antipsychotic medicines and medicines for nausea can oppose bromocriptine’s dopamine-related effects.
• Some antibiotics, antifungals and HIV medicines can alter bromocriptine exposure.
• Blood pressure medicines and medicines that cause dizziness or drowsiness may increase related effects.
• Other ergot medicines and some migraine treatments require review before combined use.
• A pharmacist should check all prescription medicines, non-prescription products and supplements against the exact product supplied.

Why Choose This Product?

• It is identified as a bromocriptine tablet with a stated strength of 1.25 mg.
• Bromocriptine has established dopamine-related effects that are relevant to particular clinical conditions.
• The stated strength can be checked against a prescription before the product is used.
• Its intended indication, formulation and Australian registration status should be confirmed for this exact tablet.

Frequently Asked Questions (FAQs)

What is the active ingredient?

The identified active ingredient is bromocriptine. Check the supplied packaging for the complete ingredient list.

What is the stated strength?

The product is presented as a 1.25 mg tablet. A pharmacist can confirm how the strength appears on the supplied pack.

What dosage form is shown?

It is presented as an oral tablet. The dosage form should be checked when the medicine is supplied.

Is this tablet approved for type 2 diabetes in Australia?

Approval for that use cannot be confirmed for this exact product. Ask a healthcare professional to check its registration and intended indication.

Is it interchangeable with other bromocriptine tablets?

Interchangeability has not been established. Strength, formulation and intended use must be considered together.

Can bromocriptine cause dizziness?

Yes. Dizziness and low blood pressure on standing are recognised effects. Severe or persistent symptoms warrant medical review.

Can it affect alertness?

Yes. Drowsiness and sudden sleep onset have been reported with bromocriptine.

What if pregnancy or breastfeeding is relevant?

Discuss this with a healthcare professional. Bromocriptine affects prolactin and can suppress milk production.

Where are the correct storage directions?

Use the directions on the packaging supplied with the tablets, or ask a pharmacist if they are unclear.

Related Products

• Bromocriptine 1.25 mg Australia
• Bromocriptine 2.5 mg Australia
• Sitagliptin 100 Mg Australia
• Acarbose 50 mg Australia
• Semaglutide 7 mg Australia
• Repaglinide 0.5 mg Australia